Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Iron deficiency in patients with solid tumours: prevalence and management in clinical practice.

de Castro J, Gascón P, Casas A, Muñoz-Langa J, Alberola V, Cucala M, Barón F.

Clin Transl Oncol. 2014 Sep;16(9):823-8. doi: 10.1007/s12094-013-1155-5. Epub 2014 Jan 24.

PMID:
24458881
2.

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.

Provencio M, Camps C, Cobo M, De las Peñas R, Massuti B, Blanco R, Alberola V, Jimenez U, Delgado JR, Cardenal F, Tarón M, Ramírez JL, Sanchez A, Rosell R.

Cancer Chemother Pharmacol. 2012 Dec;70(6):883-90. doi: 10.1007/s00280-012-1985-9. Epub 2012 Sep 29.

PMID:
23053267
3.

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, Gans S, Syrigos K, Le Marie E, Gottfried M, Vansteenkiste J, Alberola V, Strauss UP, Montegriffo E, Ong TJ, Santoro A; NSCLC [non–small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group.

J Clin Oncol. 2012 Sep 1;30(25):3084-92. doi: 10.1200/JCO.2011.39.7646. Epub 2012 Jul 30.

PMID:
22851564
4.

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D.

Lung Cancer. 2012 Jun;76(3):354-61. doi: 10.1016/j.lungcan.2011.12.002. Epub 2011 Dec 23.

PMID:
22197612
5.

[Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel].

Gasent JM, Grande E, Casinello J, Provencia M, Laforga JB, Alberola V.

Actas Urol Esp. 2011 Jan;35(1):57-60. doi: 10.1016/j.acuro.2010.09.001. Epub 2011 Jan 5. Spanish.

PMID:
21256396
6.

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.

Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM, Barón FJ, Cobo M, Maestu I, Moreno I, Mesía C, Izquierdo A, Felip E, López-Brea M, Márquez A, Sánchez-Ronco M, Tarón M, Santarpia MC, Rosell R; Spanish Lung Cancer Group.

Lung Cancer. 2011 Feb;71(2):191-8. doi: 10.1016/j.lungcan.2010.05.005.

PMID:
20627363
7.

Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.

Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, Camps C, Guijarro R, Isla D, Aguiló R, Alberola V, Padilla J, Sánchez-Palencia A, Sánchez JJ, Hermosilla E, Massuti B; Spanish Lung Cancer Group.

J Clin Oncol. 2010 Jul 1;28(19):3138-45. doi: 10.1200/JCO.2009.27.6204. Epub 2010 Jun 1.

PMID:
20516435
8.

Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.

Carcereny E, Ramirez JL, Sanchez-Ronco M, Isla D, Cobo M, Moran T, de Aguirre I, Okamoto T, Wei J, Provencio M, Lopez-Vivanco G, Camps C, Domine M, Alberola V, Sanchez JM, Massuti B, Mendez P, Taron M, Rosell R.

Lung Cancer. 2010 Jun;68(3):491-7. doi: 10.1016/j.lungcan.2009.08.004. Epub 2009 Sep 5.

PMID:
19733931
9.

Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy.

Garrido P, Rosell R, Massutí B, Cardenal F, Alberola V, Dómine M, Maeztu I, Ramos A, Arellano A; Spanish Lung Cancer Group 0008 Investigators.

Clin Lung Cancer. 2009 May;10(3):180-6. doi: 10.3816/CLC.2009.n.025.

PMID:
19443338
10.

Lung cancer and treatment in elderly patients: the Achilles Study.

Provencio M, Camps C, Alberola V, Massutti B, Viñolas N, Isla D, Dómine M, Millán I, Cobo M, Rosell R.

Lung Cancer. 2009 Oct;66(1):103-6. doi: 10.1016/j.lungcan.2008.12.021. Epub 2009 Feb 4.

PMID:
19193470
11.

[Lung cancer related anemia: prognosis factor, predictive, both or none?].

Alberola V.

Med Clin (Barc). 2008 Nov 8;131(16):612-3. Spanish. No abstract available.

PMID:
19080852
12.

Atrial flutter and myocardial infarction-like ECG changes as manifestations of left ventricle involvement from lung carcinoma.

Juan O, Esteban E, Sotillo J, Alberola V.

Clin Transl Oncol. 2008 Feb;10(2):125-7.

PMID:
18258512
13.

Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.

Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.

J Clin Oncol. 2007 Jul 1;25(19):2747-54.

PMID:
17602080
14.
15.

The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.

Rosell R, Moran T, Fernanda Salazar M, Mendez P, De Aguirre I, Ramirez JL, Isla D, Cobo M, Camps C, Lopez-Vivanco G, Alberola V, Taron M.

Rev Mal Respir. 2006 Nov;23(5 Pt 3):16S131-16S136. Review.

PMID:
17268350
16.

Methylation patterns and chemosensitivity in NSCLC.

Ramírez JL, Salazar MF, Gupta J, Sánchez JM, Taron M, Sanchez-Ronco M, Alberola V, De las Peñas R.

Adv Exp Med Biol. 2006;587:195-209. Review.

PMID:
17163167
17.

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R; Spanish Lung Cancer Group.

Ann Oncol. 2006 Apr;17(4):668-75. Epub 2006 Jan 11.

PMID:
16407418
18.

14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.

Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Peñas R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S; Spanish Lung Cancer Group.

J Clin Oncol. 2005 Dec 20;23(36):9105-12.

PMID:
16361617
19.

Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel.

Juan O, Rocher A, Sánchez A, Sánchez JJ, Alberola V.

Chemotherapy. 2005 Jul;51(4):200-5. Epub 2005 Jun 28.

PMID:
15985759
20.

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, Izquierdo A, Diz P, Camps C, Castellanos D, Alberola V, Cardenal F, Gonzalez-Larriba JL, Vieitez JM, Maeztu I, Sanchez JJ, Queralt C, Mayo C, Mendez P, Moran T, Taron M.

Ann Oncol. 2005 Jul;16(7):1081-6. Epub 2005 Apr 25.

PMID:
15851406

Supplemental Content

Loading ...
Support Center